MDP Regulatory Insight

FDA Issues 30 Warning Letters to Telehealth Firms Over Compounded GLP-1 Marketing Claims

On March 3, 2026, the U.S. Food and Drug Administration (FDA) announced that it has issued 30 warning letters to telehealth companies for making false or misleading claims regarding compounded GLP-1 products marketed on their websites.

The enforcement action marks the second wave of warning letters since the FDA launched its September 2025 initiative targeting misleading direct-to-consumer pharmaceutical advertising, particularly in digital and telehealth channels.

According to the agency, the primary violations involved implying that compounded GLP-1 products are the same as FDA-approved versions, suggesting equivalence to approved branded drugs, obscuring product sourcing, and advertising compounded products under telehealth company brand names in ways that imply the telehealth firm itself is the compounder.

FDA Commissioner Marty Makary, M.D., M.P.H., emphasized that while compounding can serve legitimate purposes like addressing drug shortages or meeting individualized patient needs, compounders must not use compounding as a pathway to circumvent FDA approval requirements.

Regulatory Context: Compounded Drugs vs. FDA-Approved Products

The FDA reiterated several key distinctions. Compounded drugs are not FDA-approved, the FDA does not review compounded products for safety, effectiveness, or quality prior to marketing, and compounded drugs are not equivalent to FDA-approved generics.

These distinctions are central to the agency’s concern. Marketing language that implies “sameness” with approved GLP-1 products risks misleading patients and blurring regulatory boundaries.

Escalating Enforcement Trend

Over the past six months, the FDA reports issuing thousands of letters to pharmaceutical and telehealth companies regarding misleading promotional practices; more than were issued during the entire previous decade.

This signals a clear shift toward more aggressive oversight of digital pharmaceutical marketing, particularly in high-demand therapeutic areas such as GLP-1 medications used for diabetes and weight management.

MDP Analysis: What This Means for Industry

This action highlights several important compliance considerations:

Telehealth Is Not a Regulatory Shortcut

Branding compounded products under telehealth company names without clear qualification raises sourcing and labeling concerns.

Sameness Claims Are High Risk

Even implied equivalence to FDA-approved GLP-1 products can trigger enforcement action.

Digital Advertising Is Under Active Surveillance

FDA’s current posture indicates ongoing monitoring of online pharmaceutical marketing practices.

Compounding Must Remain Within Statutory Boundaries

Sections 503A and 503B of the FD&C Act establish clear guardrails for compounding. Promotional overreach can jeopardize those protections.

Compliance Takeaway

Telehealth platforms, pharmacies, and outsourcing facilities must review all promotional materials for implied equivalence claims, clearly disclose compounded status where applicable, avoid brand positioning that obscures the actual compounder, and ensure marketing teams understand the regulatory distinctions between approved drugs, generics, and compounded products.

The FDA’s message is clear. Compounding is permitted within defined regulatory frameworks, but it cannot function as an alternative approval pathway.

Links

Read the FDA’s announcement here.